Pharmacological correction of hepatotoxicity induced by anti-tuberculosis drugs

Drug-induced liver injury are one of the most frequent undesirable effects of drug therapy in tuberculosis patients. Hepatoprotective drugs of various origin and chemical composition are used for the correction and prevention of drug-induced liver injury. Currently, preparations of plant origin (from milk thistle, licorice, soy), animal origin, preparations of bile acids, and some others are isolated. At the same time, there is no consistent understanding of their effectiveness, as well as consistent application algorithms, since a number of drugs have been studied only in experimental or small observational clinical studies. The article presents the mechanisms of action of the main hepatoprotective drugs, provides the evidence base of their effectiveness, and also notes their shortcomings. The most studied hepatoprotective drugs in the treatment of drug-induced liver injury is milk thistle preparation, its effectiveness has been shown not only in the treatment of drug-induced liver injury, but also in their prevention, with simultaneous administration together with tuberculosis chemotherapy, mainly in patients who initially had a high risk of developing drug-induced liver injury. Glycyrrhizic acid (licorice preparation) has shown both high preventive efficacy and pronounced therapeutic effect in LPP caused by anti-tuberculosis drugs. Essential phospholipids (highly purified extract from soybeans), in combination with B vitamins, contribute to an increase in the activity and fluidity of hepatocyte membranes, their recovery, however, they have low bioavailability, ambiguous antioxidant potential and are effective only with the cholestatic nature of the lesion. Ursodeoxycholic acid preparations are highly effective – they reduce the level of hepatocyte apoptosis, prevent toxic effects on hepatocyte membranes and on the epithelium of the bile ducts, have antioxidant and choleretic effects. Ademethionine (a drug containing amino acids and their derivatives) has cytoprotective, antioxidant and anticholestatic effects, also has anti-neurotoxic and antidepressant effects. A combination of ademethionine, succinic acid, inosine and nicotinamide showed a good therapeutic effect, which allows to quickly reduce the severity of clinical symptoms of hepatotoxicity and normalize laboratory parameters. In general, the available data make it possible to effectively prevent and stop toxic liver lesions in the treatment of tuberculosis patients. A variety of hepatoprotective drugs with various pharmacological effects (anti-cytolytic, anti-cholestatic, anti-apoptotic, antioxidant, immunomodulatory) provide an opportunity for a rational choice of a drug in various clinical situations.

1. Koroleva M. V. Hepatoprotective properties and pharmacodynamics of drugs that affect metabolic processes in patients with exogenous toxic liver damage. Avtoref. dis. … d-ra med. nauk. Volgograd, 2015.

2. Dolgushina A. I., Volchegorsky I. A., Novoselov P. N., Ushkareva E. V., Olevskaya E. R., Kuznetsova A. S. Antituberculosis drug-induced hepatotoxicity // Eksperimentalnaya i klinicheskaya gastroenterologiya. 2018; 156 (8): 116-124. (In Russ.)

3. Okovityy S. V., Prikhod' ko V. A., Bezborodkina N. N., Kudryavtsev B. N. Hepatoprotectors: a guide for physicians. 2-ye izd., pererab. i dop. M.: GEOTAR-Media, 2022. P. 240.

4. Mekhtiyev S. N., Okovityy S. V., Mekhtiyeva O. A. Principles of choosing hepatoprotectors in the practice of a therapist // The Lechaschi Vrach Journal. 2016; 8: 44.

5. Ivanova D. A., Borisov S. Ye., Ivanushkina T. N. i dr. Drug-induced liver damage in patients with tuberculosis: treatment and prevention with hepatotropic drugs. Metodicheskiye rekomendatsii. M., 2017. P. 50.

6. Starshinova A.A., Belyaeva E. N., Panteleev A. M., Pavlova M. V. Use of hepatoprotectors during tuberculosis chemotherapy: review of the russian and international studies // Tuberkulez i bolezni legkikh. 2018; 96 (10): 63-69. (In Russ.)

7. Petrov V. I., Sabanov A. V., Frolov M. Yu. Clinical pharmacology of drugs used in diseases of the liver, biliary tract and pancreas / V kn.: Klinicheskaya farmakologiya: natsional'noye rukovodstvo / Pod red. Yu. B. Belousova, A. G. Kukesa, V. K. Lepakhina, V. I. Petrova. M.: GEOTAR-Media, 2009. P. 831-854.

8. Kurchenko V. P., Shchekatikhina A. S. Content of flavolignans of milk thistle in fruits and hepatoprotector medicines // Retsept. 2019; 2: 225-231. (In Russ.)

9. Lukyanova L. D., Germanova E. L., Lysko A. I. Energotropic, antihypoxic, and antioxidative effects of phytogenous flavo-noid-containing agents // Vestnik Rossiiskoi akademii meditsinskikh nauk. 2007; 2: 55-62. (In Russ.)

10. Chien C. F., Wu Y. T., Tsai T. H. Biological analysis of herbal medicines used for the treatment of liver diseases // Biomedical Chromatography. 2011; 25 (1-2): 21-38.

11. Eminzade S., Uras F., Izzettin F. V. Silymarin protects liver against toxic effects of anti-tuberculosis drugs in experimental animals // Nutrition & Metabolism. 2008; 5 (1): 1-8.

12. Singh M., Sasi P., Gupta V. H., et al. Protective effect of curcumin, silymarin and N-acetylcysteine on antitubercular drug-induced hepatotoxicity assessed in an in vitro model // Human & experimental toxicology. 2012; 31 (8): 788-797.

13. Kucheryavyy Yu. A., Morozov S. V. Hepatoprotectors: rational aspects of application: textbook. M.: Forte Print, 2012. p. 36.

14. Matveyev A. V., Konyayeva Ye. I., Kurchenko V. P., Shchekatikhina A. S. Hepatoprotective properties of silymarin // Eksperimental'naya i klinicheskaya gastroenterologiya. 2011; 2: 130-135.

15. Kazyulin A. N., Shestakov V. A., Goncharenko A. Ju., Pavleeva E. E., Lubeznova I. Ju. Preparations of standardized silymarin. mechanisms of action and prospects for clinical application // Eksperimentalnaya i klinicheskaya gastroenterologiya. 2018; 7 (155): 73-85. (In Russ.)

16. Zhang S., Pan H., Peng X., et al. Preventive use of a hepatoprotectant against anti-tuberculosis drug-induced liver injury: A randomized controlled trial // J Gastroenterol Hepatol. 2016; 31 (2): 409-416.

17. Heo E., Kim D. K., Oh S. H., et al. Effect of Prophylactic Use of Silymarin on Anti-tuberculosis Drugs Induced Hepatotoxicity // Tuberc Respir Dis (Seoul). 2017; 80 (3): 265-269.

18. Luangchosiri C., Thakkinstian A., Chitphuk S., et al. A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury // BMC complementary and alternative medicine. 2015; 15 (1): 1-7.

19. Belousova N. S. An experience of using an original milk thistle-based hepatoprotector in therapy of non-alcoholic fatty liver disease against the background of antituberculosis therapy // Infektsionnye bolezni. 2016; 14 (3): 61-66. (In Russ.)

20. Shi Z., Wu J., Yang Q., et al. Efficacy and safety of milk thistle preventive treatment of anti-tuberculosis drug-induced liver injury: A protocol for systematic review and meta-analysis // Medicine (Baltimore). 2020; 52 (99).

21. Gong J. Y., Ren H., Peng S. Y., et al. Comparative effectiveness of glycyrrhizic acid preparations aimed at preventing and treating anti-tuberculosis druginduced liver injury: A network meta-analysis of 97 randomized controlled trials // Phytomedicine. 2022; 98 (153942).

22. Ryasenskiy D. S., Aseev A. V., Elgali A. I. Effect of glycyrrhizic acid on the membrane structures of mononuclear cells in pulmonary tuberculosis patients receiving anti-tuberculosis chemotherapy // Tuberkulez i bolezni legkikh. 2018; 96 (10): 35-40. (In Russ.)

23. Shirokova Y. N. Druginduced liver diseases // Rossiiskie meditsinskie vesti. 2011; 16 (3): 23-29. (In Russ.)

24. Liu X., Li X. An Observation of Essentiale's Efects on the Liver Protection during the Medical Treatment of Tuberculosis // Journal of Clinical Pulmonary Medicine. 2002; 7 (1): 18-19.

25. Lazebnik L. B., Golovanova E. V., Hlynova O. V. Medicinal liver damage in adults // Eksperimentalnaya i klinicheskaya gastroenterologiya. 2020; 2 (174): 29-54. (In Russ.)

26. Udut V. V., Vengerovskiy A. I., Burkova V. N., Karkishchenko N. N. Influence of hepatoprotectors of phospholipid nature on lipid peroxidation of the liver and the content of blood cytokines in experimental pathology caused by isoniazid // Eksperimental'naya i klinicheskaya gastroenterologiya. 2012; 6: 47-52.